CAR T-cell therapy effective in patients with blood cancer regardless of race: Study
Patients with multiple myeloma treated with idecabtagene vicleucel, known as "ide-cel," a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according ...
Oct 19, 2023
0
1